Stella Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-778	-137	-760	-775	-764
Depreciation & Amortization	28	34	35	35	34
Other Operating Activities	4	-2	-1	-2	-
Change in Accounts Receivable	646	-638	-16	-42	38
Change in Inventory	-65	-114	-175	-166	-380
Change in Accounts Payable	-150	-88	26	108	-13
Change in Other Net Operating Assets	-19	1,085	15	15	4
Operating Cash Flow	-334	140	-876	-827	-1,081
Capital Expenditures	-11	-4	-10	-26	-46
Sale (Purchase) of Intangibles	-	-8	-	-3	-
Investment in Securities	-	300	-	-	-304
Other Investing Activities	-4	-1	1	-	-
Investing Cash Flow	-15	287	-9	-29	-350
Long-Term Debt Issued	139	730	-	-	-
Long-Term Debt Repaid	-158	-946	-160	-160	-160
Net Debt Issued (Repaid)	-19	-216	-160	-160	-160
Issuance of Common Stock	-	941	388	451	3,616
Other Financing Activities	-14	-4	-	-	373
Financing Cash Flow	-33	721	228	291	3,829
Miscellaneous Cash Flow Adjustments	-1	1	-	-	-1
Net Cash Flow	-383	1,149	-657	-565	2,397
Free Cash Flow	-345	136	-886	-853	-1,127
Free Cash Flow Margin	-106.81%	14.15%	-329.37%	-372.49%	-1127.00%
Free Cash Flow Per Share	-10.14	4.07	-28.60	-29.54	-40.13
Cash Interest Paid	5	4	2	2	3
Cash Income Tax Paid	2	2	2	3	-
Levered Free Cash Flow	-79.5	-859.75	-612.25	-569	-828
Unlevered Free Cash Flow	-75.13	-857.25	-611	-567.75	-826.13
Change in Working Capital	412	245	-150	-85	-351